Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

STRATA Skin Sciences (SSKN) Gross Profit (2016 - 2025)

Historic Gross Profit for STRATA Skin Sciences (SSKN) over the last 13 years, with Q3 2025 value amounting to $4.2 million.

  • STRATA Skin Sciences' Gross Profit fell 2084.75% to $4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.8 million, marking a year-over-year decrease of 212.19%. This contributed to the annual value of $19.1 million for FY2024, which is 335.84% up from last year.
  • STRATA Skin Sciences' Gross Profit amounted to $4.2 million in Q3 2025, which was down 2084.75% from $4.3 million recorded in Q2 2025.
  • Over the past 5 years, STRATA Skin Sciences' Gross Profit peaked at $6.8 million during Q4 2022, and registered a low of $3.1 million during Q1 2024.
  • Over the past 5 years, STRATA Skin Sciences' median Gross Profit value was $4.8 million (recorded in 2023), while the average stood at $4.8 million.
  • As far as peak fluctuations go, STRATA Skin Sciences' Gross Profit soared by 14241.34% in 2021, and later tumbled by 2989.19% in 2023.
  • Quarter analysis of 5 years shows STRATA Skin Sciences' Gross Profit stood at $6.0 million in 2021, then rose by 14.13% to $6.8 million in 2022, then dropped by 29.89% to $4.8 million in 2023, then increased by 17.1% to $5.6 million in 2024, then fell by 25.58% to $4.2 million in 2025.
  • Its last three reported values are $4.2 million in Q3 2025, $4.3 million for Q2 2025, and $3.6 million during Q1 2025.